Filament Health is the world’s leading exclusively-natural psychedelic drug discovery and extraction company. With deep experience in natural extraction technology and commercialization, a robust and innovative IP portfolio, in-house GMP manufacturing, and a Health Canada psilocybin Dealer’s License, Filament Health has built the foundation to support a rapidly-scaling drug development pipeline. The company’s first drug candidates, proprietary GMP-grade psychoactive mushroom extract formulations, are poised to enter into Phase I and Phase II FDA clinical trials in the second half of 2021. 

Filament’s mission is to get safe, natural, FDA-approved psychedelic extracts into the hands of everyone who needs them as soon as possible.